CA2385665A1 - Modulation de l'activite de l'enos et ses utilisations - Google Patents

Modulation de l'activite de l'enos et ses utilisations Download PDF

Info

Publication number
CA2385665A1
CA2385665A1 CA002385665A CA2385665A CA2385665A1 CA 2385665 A1 CA2385665 A1 CA 2385665A1 CA 002385665 A CA002385665 A CA 002385665A CA 2385665 A CA2385665 A CA 2385665A CA 2385665 A1 CA2385665 A1 CA 2385665A1
Authority
CA
Canada
Prior art keywords
vegf
enos
receptor
kdr
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002385665A
Other languages
English (en)
Inventor
Ben-Quan Shen
Thomas Zioncheck
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2385665A1 publication Critical patent/CA2385665A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La présente invention concerne l'utilisation de VEGF (vascular endothelial growth factor / facteur de croissance endothéliale vasculaire) ou d'agonistes de récepteurs VEGF pour la régulation vers le haut de l'expression et de l'activité de l'eNOS (endothelial nitric oxide synthase / synthase endothéliale de l'oxyde nitrique). Le VEGF et les agonistes de récepteurs VEGF peuvent être utilisés pour le traitement ou la prévention de l'hypertension, des diabètes, de l'angine, de la thrombose, de l'athérosclérose, de l'insuffisance cardiaque, et d'autres états pathologiques ou troubles dans lesquels l'oxyde nitrique est un important régulateur.
CA002385665A 1999-11-02 2000-11-02 Modulation de l'activite de l'enos et ses utilisations Abandoned CA2385665A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US16313299P 1999-11-02 1999-11-02
US60/163,132 1999-11-02
PCT/US2000/030294 WO2001032695A2 (fr) 1999-11-02 2000-11-02 MODULATION DE L'ACTIVITE DE L'eNOS ET SES UTILISATIONS

Publications (1)

Publication Number Publication Date
CA2385665A1 true CA2385665A1 (fr) 2001-05-10

Family

ID=22588624

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002385665A Abandoned CA2385665A1 (fr) 1999-11-02 2000-11-02 Modulation de l'activite de l'enos et ses utilisations

Country Status (6)

Country Link
EP (1) EP1225910A2 (fr)
JP (1) JP2003513105A (fr)
AU (1) AU782158B2 (fr)
CA (1) CA2385665A1 (fr)
IL (1) IL148674A0 (fr)
WO (1) WO2001032695A2 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101123879A (zh) * 2004-08-20 2008-02-13 约翰·霍普金斯大学 血管新生治疗方法
EP2370581B1 (fr) * 2008-12-04 2016-08-03 CuRNA, Inc. Traitement de maladies apparentées au facteur de croissance de l'endothélium vasculaire (vegf) par inhibition du transcript antisens naturel du vegf

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6448077B1 (en) * 1994-02-10 2002-09-10 Imclone Systems, Inc. Chimeric and humanized monoclonal antibodies specific to VEGF receptors
US6020473A (en) * 1995-08-25 2000-02-01 Genentech, Inc. Nucleic acids encoding variants of vascular endothelial cell growth factor
US6750044B1 (en) * 1996-10-17 2004-06-15 Genentech, Inc. Variants of vascular endothelial cell growth factor having antagonistic properties, nucleic acids encoding the same and host cells comprising those nucleic acids
EP1488761A1 (fr) * 1996-11-01 2004-12-22 Ark Therapeutics Limited Dispositif pour administrer un agent thérapeutique à un vaisseau sanguin
DK1112083T3 (da) * 1998-09-09 2004-03-08 Univ Washington Behandling af mikrovaskulære angiopatier
JP2002541849A (ja) * 1999-04-16 2002-12-10 ジェネンテック・インコーポレーテッド 血管内皮細胞増殖因子変異体とその用途
JP2003507006A (ja) * 1999-05-20 2003-02-25 サイオス，インコーポレーテッド 血管内皮増殖因子改変体

Also Published As

Publication number Publication date
EP1225910A2 (fr) 2002-07-31
JP2003513105A (ja) 2003-04-08
AU782158B2 (en) 2005-07-07
WO2001032695A3 (fr) 2002-02-14
IL148674A0 (en) 2002-09-12
WO2001032695A2 (fr) 2001-05-10
AU1756501A (en) 2001-05-14

Similar Documents

Publication Publication Date Title
US6750044B1 (en) Variants of vascular endothelial cell growth factor having antagonistic properties, nucleic acids encoding the same and host cells comprising those nucleic acids
US20060063203A1 (en) Vascular endothelial cell growth factor variants and uses thereof
US7045133B2 (en) VEGF-D/VEGF-C/VEGF peptidomimetic inhibitor
EP0851920B1 (fr) Variants du facteur de croissance des cellules de l'endothelium vasculaire, leurs utilisations et leurs procedes de fabrication
US20060188503A1 (en) Modulation of eNOS activity and therapeutic uses thereof
Rezzola et al. Therapeutic potential of anti-angiogenic multitarget N, O-sulfated E. coli K5 polysaccharide in diabetic retinopathy
AU782158B2 (en) Modulation of eNOS activity and therapeutic uses thereof
US20060269997A1 (en) Vascular endothelial cell growth factor variants and uses thereof
RU2392963C2 (ru) Синтетические варианты гипергликозилированного протеазо-резистентного полипептида, пероральные композиции и способы применения таких вариантов
JP2001500384A (ja) 変化した薬理学的特性を持つ血管内皮細胞増殖因子の変異体とその関連態様
CN116234541A (zh) 通过EpoR拮抗剂治疗疾病
AU2004202596B2 (en) Vascular endothelial cell growth factor variants and uses thereof
CN101070343A (zh) 血管内皮细胞生长因子变体及其应用

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued